150 likes | 528 Views
Pancoast syndrome. Superior Pulmonary Sulcus Tumor. Henry Pancoast. First professor of roentgenology at the University of Pennsylvania. Reported several cases of the syndrome in 1924 JAMA article. Described clinical features of the
E N D
1. Morning report Bridger Clarke
10/22/08
2. Pancoast syndrome Superior Pulmonary Sulcus Tumor
3. Henry Pancoast First professor of roentgenology at the University of Pennsylvania.
Reported several cases of the syndrome in 1924 JAMA article.
Described clinical features of the “superior sulcus tumor” in his presidential address to the AMA in 1932.
4. Pancoast Tumor “Pancoast Tumor” is a neoplasm located at the apical pleuropulmonary groove adjacent to the subclavian vessels.
Symptoms arise as a result of neoplastic involvement of the brachial plexus, nerve roots, sympathetic chain, ribs, and chest wall.
5. Symptoms Shoulder pain- present in 44-96%.
Most common initial symptom.
Extends down ulnar aspect of arm with T1 and C8 nerve root involvement.
6. Symptoms Neurological- present in 8-22%
Weakness and atrophy of the intrinsic hand muscles
Paresthesias of the medial aspect of the arm
Spinal chord compression and paraplegia occur in 5% of patients.
7. Symptoms Horner’s Syndrome-
Ptosis, miosis, anhydrosis.
Caused by involvement of the paravertebral sympathetic chain and the stellate ganglion.
8. Symptoms Other Manifestations-
Superior vena cava syndrome
Recurrent laryngeal nerve involvement
Due to peripheral location of tumor, pulmonary symptoms such as cough, hemoptysis, and dyspnea occur late.
9. Etiology Non-small cell lung cancer accounts for 90-95% of cases. Primarily squamous cell carcinoma.
Other lesions arising in the superior sulcus: adenoid cystic carcinoma, mesothelioma, lymphoma, vascular aneurysms, amyloid nodules, TB, hydatid cysts, fungi.
10. Diagnosis: imaging
11. Diagnosis Sputum cytology: ~15% yield
Bronchoscopy: 30-40% yield
CT-guided biopsy: 90-95% yield
VATS or thoracotomy: if less invasice techniques are nondiagnostic.
12. Staging Identical to NSCLC elsewhere in thorax
At least stage T3 given involvement of chest wall
Invasion of vertebral body or subclavian vessels increases stage to T4
13. Treatment Typically a combination of surgical resection and radiation (pre- or post-op).
Induction chemotherapy prior to radiation may have mortality benefit.
14. Prognostic Factors 5 year survival with uninvolved nodes 30-40%.
<10% with lymph node involvement.
Poor Survival:
Horner’s syndrome
Mediastinal lymph node involvement
Incomplete resection
Invasion of vertebral bodies
15. The End